2010年，由IBC主办，关于创药及新药开发的第5届学会将在日本举办

请期待这场主题、会场、日程，全部焕然一新的学会

从关注国际性的合作、亚洲的新兴市场、日本国内的法规、革新性研发的展望等主题而举办的第1届大会，到焦点集中在蛋白质科学、抗体疗法、从初期创药阶段到概念验证(POC)阶段的期间短缩等主题的上一届大会，本学会一贯追踪日本制药业界中的各种趋势，并持续反映出身为世界第二大医药品市场的日本的复杂需求。

在基本方针设定为提供对应日本需求之最准确情报的本届学会中，除了小分子、抗体、蛋白药物、寡核苷酸、缩氨酸等之外，亦将讨论创药、新药开发、诊断及行销等主题，并将介绍能吸引日本境内大小规模的制药企业的注意力及激荡出新构想的最高等级重要情报。此外，自本届开始，学会亦重新命名，以赋予各种主题新的观点，并吸引在日本制药业界扮演重要角色的人物。

会议的注目焦点

关于策略性主题的讨论：

• 日本之抗体开发的未来愿景－分析此一与他国相比明显落后的领域的现况，摸索新的可能性
• 生产性低落与领导地位－检讨收购与合并的有效性，寻求日本的医疗尚无对应的需求
• 全球化与地区化－考虑关于参与亚洲新兴市场，探索日本在扩大中的亚洲市场里所占有的地位
• 日本之学名药（Generics）及生技学名药（Biogenerics）的影响－分析政府的压力与业界内的各种动态

科学领域的会议时段：

• iPS细胞/再生医疗
• 分子标的治疗
• 次世代抗体与蛋白质科学
• 个别化医疗与诊断
• RNA干扰(RNAi)技术的开发
• 强化新制品开发的开放性技术革新/研究开发策略
• 新兴市场中的新药开发与临床研究
• 日本的生物科技技术

Strengthen your Pipeline with New Opportunities in Open Innovation, Next Generation Biologics, Personalized Medicine, Stem Cells and Targeted Cancer Therapies

The Drug & Biologics Japan event aims to address the changing paradigms in Japan's pharmaceutical industry - shifting from small molecules to antibody/protein science and stem cells, from traditional drug discovery to molecularly targeted therapies and personalized medicine strategies. You will hear from over 50 speakers from 10 countries, including USA, UK, Japan, Germany, Belgium, Switzerland, Australia, Israel, China and India, who will share their current strategies, ongoing developments and proven successes.

Network with over 50 speakers and get first-hand information on:

• Transforming ideas into innovation and bridge the gap between inspiration and implementation
• Alternative scaffolds, conjugates or bispecific antibodies - How you can leapfrog into the current developments
• Personalized medicine, pharmacogenomics, biomarkers and diagnostics - Overcoming challenges to implementation
• Science, technology and therapeutic applications of iPS cells, ES cells and adult stem cells - Industry-academia collaborations to bring therapies faster-to-market
• Targeting ARQ197, CICs, P2X7 and other novel molecular targets - Working to towards a breakthrough in cancer therapeutics

Open Innovation
Governments in various parts of the world are actively supporting innovation - more specifically, Open Innovation. It has become increasingly necessary for inventors and their firms to exploit information and capabilities outside the firm in order to combine one's own resources with resources from the external environment. This session will explore how "open innovation" is influencing Japanese pharma and healthcare industry to modify their innovation strategies to enhance their creativity and productivity.

Next Generation Biologics
Covering topics on ADC, alternative scaffolds, bispecific and multispecific antibodies, immunogenicity, preclinical and clinical development updates, the session offers insights into the current stateof- the-art developments in next generation biologics from around the world. Japanese pharmaceutical and biotech companies already in the space or planning to enter the space cannot afford to miss this session.

Stem Cells
Stem cells is one of the fastest growing areas of research throughout the world, and Japan is ranked among the top research centers for stem cell science and technology. This session will bring together experts from academia and industry to discuss the science and therapeutic applications of iPS cells, ES cells, mesenchymal stem cells etc.

Personalized Medicine & Biomarkers
Personalized medicine or "order-made medicine" as it is known in Japan, is a major initiative not only by the Japanese government but also throughout the world's pharmaceutical industry. In this session, we will hear from leading pharmaceutical companies like Wyeth and AstraZeneca on how they are incorporating personalized medicine and biomarkers in their drug development strategies.

Molecularly Targeted Cancer Therapies
A new frontier in cancer drug development has emerged - where scientists are now focusing on developing drugs that target the molecular alterations involved in the biological pathways in cancer. Hear from Kyowa Hakko Kirin, Daiichi Sankyo, RIKEN, BioSceptre and ArQule as they present their latest therapeutic developments that aim to block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression.